• Zentalis Pharmaceuticals recently reported that a 400mg once-daily, 5-days-on/2-days-off regimen of azenosertib was selected as the optimal monotherapy dose for Cyclin E1-positive platinum-resistant ovarian cancer, following a prespecified interim analysis from the DENALI Part 2a Phase 2 trial.
• This dose decision, supported by a differentiated response rate, comparable safety and plans for inclusion in both the pivotal DENALI Phase 2 and confirmatory ASPENOVA Phase 3 trials, is central to Zentalis’s pursuit of a potential accelerated approval pathway in this biomarker-selected population.
• With this dose now guiding both ongoing and planned trials, we’ll explore how it reshapes Zentalis’s investment narrative around azenosertib.

Outshine the giants: these 21 early-stage AI stocks could fund your retirement.

What Is Zentalis Pharmaceuticals' Investment Narrative?

To be comfortable holding Zentalis today, you really need to believe that azenosertib can translate its Cyclin E1-focused ovarian cancer program into a real, approvable product before the cash burn and execution risk catch up with it. The new 400 mg dosing decision tightens the story: it simplifies the registrational path, keeps DENALI and ASPENOVA aligned, and helps justify the recent sharp share price move as more than just speculation. In the near term, the main catalyst remains DENALI progress toward the year-end 2026 topline readout, with Fast Track status and the expanded Part 2c cohort incrementally supporting the accelerated approval narrative. On the flip side, Zentalis is still loss-making with no revenue, a relatively new leadership team, insider selling and a volatile stock, so the downside if the data underwhelm remains very real.

However, investors should not ignore how dependent this story is on one late-stage asset. Zentalis Pharmaceuticals' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Two fair value views from the Simply Wall St Community span roughly US$5.81 to US$21.11 per share, underlining how far apart individual expectations can be. When you overlay that with azenosertib’s binary late-stage trial risk and Zentalis’ ongoing losses, it becomes clear why some participants see deep opportunity while others focus on the possibility of further setbacks.

Explore 2 other fair value estimates on Zentalis Pharmaceuticals - why the stock might be worth 12% less than the current price!

Reach Your Own Conclusion

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Zentalis Pharmaceuticals research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Zentalis Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zentalis Pharmaceuticals' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.